Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. reports developments across its global medical technology business, including orthopedic reconstructive implants, surgical products, and integrated digital and robotic technologies that use data, analytics and artificial intelligence. Company updates commonly cover quarterly results and guidance, dividend actions, health care conference appearances, executive leadership changes, and clinical or operational data presented at orthopedic meetings.
Product-focused announcements describe musculoskeletal care technologies such as Oxford Cementless Partial Knee, Persona OsseoTi Keel Tibia, and HAMMR Automated Hip Impaction System, alongside broader portfolio themes in knees, hips, smart implants, robotics, AI and medical education.
Zimmer Biomet (ZBH) announced several Americas leadership promotions and a restructuring of its commercial organization effective October 1, 2026.
Gary Campbell will become President, Americas, overseeing commercial strategy and execution in the United States, Canada and Latin America and continuing to evolve the U.S. go-to-market model. Brian Hatcher will be promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery, expanding his remit to include Global Knees and Hips and leading global portfolio strategy across most of the company’s businesses. Bradley Kessler will become President, Americas – Robotics, Technology and Data, responsible for driving robotics, digital and technology solutions in the Americas and supporting the anticipated 2027 launch of the Monogram next-generation orthopedic robot.
As part of the restructuring, Kevin Thornal, Group President, Global Businesses and the Americas, will leave the company on September 30, 2026. Zimmer Biomet also reiterated its full-year 2026 financial outlook previously provided on August 5, 2026.
Zimmer Biomet (NYSE: ZBH) declared a quarterly cash dividend of $0.24 per share for the third quarter of 2026. The dividend is payable on or about October 30, 2026 to shareholders of record as of the close of business on September 30, 2026.
Zimmer Biomet (NYSE: ZBH) reported second quarter 2026 net sales of $2.177 billion, up 4.8% reported, 4.7% constant currency and 4.0% organic constant currency versus the prior year. Net earnings were $198.3 million, with diluted EPS of $1.03, up 33.8%, and adjusted diluted EPS of $2.07, consistent with last year.
Q2 operating cash flow was $447.9 million and free cash flow $308.3 million. The company raised 2026 reported revenue growth guidance to 3.9%-4.9% and adjusted EPS to $8.47-$8.59, and increased expected 2026 share repurchases to up to $1 billion. Hips, S.E.T. and Technology & Data categories led growth, while Knees were roughly flat. Zimmer Biomet also highlighted FDA 510(k) clearance and first cases of its next-generation ROSA Shoulder System.
Zimmer Biomet (NYSE: ZBH) appointed Chintan Desai as president of its Asia Pacific region, effective immediately. Desai joins from Alcon, where he held senior international and Asia Pacific leadership roles, following a 22-year career at GE Healthcare in multiple regional positions.
His background spans sales, marketing, services, supply chain, finance and project management across medical devices and related sectors. Desai succeeds Sang Yi, group president of Asia Pacific, who will leave the company on August 28, 2026, after a transition period.
Zimmer Biomet (NYSE: ZBH) will host a webcast and conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026 at 8:30 a.m. ET. A news release with detailed results will be issued at 6:30 a.m. ET the same day. The live audio webcast and replay will be accessible via the company’s Investor Relations website, with U.S./Canada dial-in at (800) 330-6710 and international dial-in at +1 (213) 279-1505, both using conference ID 7090861.
Zimmer Biomet (NYSE:ZBH) announced that its management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8. A fireside chat is scheduled for 10:40 a.m. ET, with a live audio webcast and replay available on the company’s investor relations website.
Zimmer Biomet (NYSE: ZBH) announced that its Board approved a quarterly cash dividend for the second quarter of 2026. The dividend is $0.24 per share, payable on or about July 31, 2026 to stockholders of record at the close of business on June 25, 2026.
Zimmer Biomet (NYSE: ZBH) announced it now expects to repurchase up to $1 billion of common stock in fiscal 2026, a $250 million increase from its prior assumption.
All buybacks will occur under the existing $1.5 billion authorization approved in February 2026.
Zimmer Biomet (NYSE: ZBH) announced management will participate in the Bank of America Securities Health Care Conference on Wednesday, May 13, 2026, with a fireside chat at 8:40 a.m. PT (11:40 a.m. ET). A live audio webcast will be available on the company Investor Relations website and for replay after the session.
Zimmer Biomet (NYSE: ZBH) reported Q1 2026 net sales of $2.087 billion, up 9.3% reported, 6.8% constant currency and 2.9% organic constant currency. GAAP net earnings were $238.1 million and adjusted net earnings $409.4 million. Diluted EPS was $1.22 and adjusted diluted EPS $2.09. The company generated $359.4 million operating cash flow and $245.9 million free cash flow, repurchased $250 million of shares, and raised 2026 adjusted EPS and FCF expectations.